Your browser doesn't support javascript.
loading
Molecular prediction of clinical response to anti-PD-1/anti-PD-L1 immune checkpoint inhibitors: New perspectives for precision medicine and mass spectrometry-based investigations.
Longuespée, Rémi; Theile, Dirk; Zörnig, Inka; Hassel, Jessica C; Lindner, Joshua Raoul; Haefeli, Walter E; Fresnais, Margaux.
Afiliación
  • Longuespée R; Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University Hospital, Heidelberg, Germany.
  • Theile D; Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University Hospital, Heidelberg, Germany.
  • Zörnig I; Department of Medical Oncology and National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany.
  • Hassel JC; Department of Dermatology and National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany.
  • Lindner JR; Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University Hospital, Heidelberg, Germany.
  • Haefeli WE; Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University Hospital, Heidelberg, Germany.
  • Fresnais M; Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University Hospital, Heidelberg, Germany.
Int J Cancer ; 153(2): 252-264, 2023 07 15.
Article en En | MEDLINE | ID: mdl-36408912
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Medicina de Precisión / Inhibidores de Puntos de Control Inmunológico Tipo de estudio: Prognostic_studies / Risk_factors_studies / Screening_studies Límite: Humans Idioma: En Revista: Int J Cancer Año: 2023 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Medicina de Precisión / Inhibidores de Puntos de Control Inmunológico Tipo de estudio: Prognostic_studies / Risk_factors_studies / Screening_studies Límite: Humans Idioma: En Revista: Int J Cancer Año: 2023 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Estados Unidos